Effect of bismuth subgallate on nitric oxide and prostaglandin E2 production by macrophages.
Bismuth subgallate (BSG) is used widely in clinics, including Vincent's angina, syphilis, and adenotonsillectomy. This study examined the effects of BSG on nitric oxide (NO) and prostaglandin E2 (PGE2) production in activated RAW 264.7 cells. BSG suppressed production of NO and PGE2 in a dose-dependent manner. BSG could increase TGF-beta1 production, which in turn might promote degradation of iNOS mRNA, thus inhibiting NO production. Additionally, BSG inhibited mPGES protein expression and COX-2 activity in activated RAW 264.7 cells. Exogenous addition of SNP reversed the inhibition effect of PGE2 production by BSG. This behavior indicates that PGE2 inhibition by BSG exerts an indirect effect through NO inhibition.
Lin
Chia-Yen
CY
Institute of Biochemistry, School of Life Science, National Yang-Ming University, 155, Li-Nong St., Sec. 2, Peitou, Taipei, Taiwan, ROC.
Shen
Yi-Hsuan
YH
Wu
Szu-Hui
SH
Lin
Chi-Hung
CH
Hwang
Shiaw-Min
SM
Tsai
Ying-Chieh
YC
D000818:Animals; D015152:Blotting, Northern; D015153:Blotting, Western; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D004926:Escherichia coli / Q000737:chemistry; D005707:Gallic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D052247:Nitric Oxide Synthase Type II; D009578:Nitrobenzenes / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D009942:Organometallic Compounds / Q000494:pharmacology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis / Q000378:metabolism; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D011994:Recombinant Proteins; D013449:Sulfonamides / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000096:biosynthesis
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008070:Lipopolysaccharides; D020030:Nitric Oxide Donors; D009578:Nitrobenzenes; D009942:Organometallic Compounds; D012333:RNA, Messenger; D011994:Recombinant Proteins; D013449:Sulfonamides; D016212:Transforming Growth Factor beta; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D009599:Nitroprusside; D009569:Nitric Oxide; D005707:Gallic Acid; D007371:Interferon-gamma; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone; C002170:bismuth subgallate